Medical Advocates
Zidovudine (Retrovir)
 
Perinatal Data
New and Noteworthy
 Animal; Studies
General Reports
 Guidelines
 Pharmacokinetics
 Safety
 Resistance
Adverse Events
 Patient Perceptions
 Adherence
 Efficacy
 






 
ZDV Main Page Main New/Newsworthy Home Page

Last Update:  August 21, 2008  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
 
August 2008
 
Animal Studies
 
         Journal Papers, Abstracts, and Commentaries
 
  Mitochondrial Damage Revealed by Morphometric and Semiquantitative Analysis
of Mouse Pup Cardiomyocytes Following in Utero and Postnatal Exposure to
Zidovudine and Lamivudine.
 Bishop JB, Tani Y, Witt K, et al.
Toxicol Sci. 2004 Jun 30
Abstract
General Reports/Reviews
 

        Journal Papers, Abstracts, and Commentaries

 
Factors associated with zidovudine receipt and prenatal care among HIV-infected pregnant women in New Jersey.
 Abatemarco DJ, Catov JM, Cross H, et al 
J Health Care Poor Underserved. 2008 Aug;19(3):814-28.
 Abstract
 
High levels of AZT and its intracellular phosphate metabolites in AZT and
AZT/3TC-treated newborns of HIV-infected mothers.
 Durand-Gasselin L, Pruvost A, et al  
Antimicrob Agents Chemother. 2008 Apr 21
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
AZT Availability in Illinois Birthing Hospitals: Is the Perinatal HIV Prevention Safety Net in
Place?
Eary RL, Borders AE, Handler A, et al
Matern Child Health J. 2007 Jan 23
 Abstract
 
HIV Infection and Zidovudine Use in Childbearing Women.
 Sia J, Paul S, Martin RM, Cross H.
Pediatrics. 2004 Nov 15
Abstract

Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and
after the introduction of zidovudine prophylaxis.
The Italian Register for Human Immunodeficiency Virus Infection in Children
Arch Pediatr Adolesc Med 2002 Sep;156(9):915-2
 Abstract

Zidovudine: A Review of its Use in the Management of Vertically-Acquired Pediatric
HIV infection.  
Bhana N,Ormrod D, Perry CM, et al.
 Paediatr Drugs 2002;4(8):515-53
 Abstract

  

        Conference Reports, Abstracts, and Posters

 
Is stopping zidovudine/single-dose nevirapine safer than stopping combination antiretroviral
treatment in women after delivery who do not require therapy for their own health?
Phanuphak N, Apornpong T, Limpongsanurak S, et al
 (4th IAS Conference)
 Abstract
 
Anti-inflammatory cytokine profile in term placentae of HIV-1 infected women receiving
antiretrovirals for the prevention of mother-to-child transmission in Thailand
Pornprasert S, Mary J-Y, Faye A, et al
 (4th IAS Conference)
 Abstract
 
Infant feeding choices of HIV-1-infected pregnant women receiving either HAART or short-
course ARV (zidovudine+nevirapine) transmission prophylaxis: preliminary data from Nairobi
(Kesho Bora study)
Gichuhi C., Kose J., Arum S., et al
 (XVI International AIDS Conference)
 Abstract
 
Evolution of hematologic parameters in Thai HIV-infected pregnant women initiating zidovudine
prophylaxis at 28 weeks’ or 35 weeks gestation
Briand N., Le Coeur S., Jourdain G., et al
 (XVI International AIDS Conference)
 Abstract

Modeling of the Timing of Mother-to-Child HIV-1 Transmission as a Function
of Zidovudine Treatment Duration in Mothers and Infants
 S Prasitwattanaseree, D Costagliola, M Lallemant, JY Mary
 (12 CROI)
Abstract

FEASIBILITY, COST-EFFECTIVENESS OF A MATERNAL ZIDOVUDINE (ZDV)
TREATMENT STARTING AT 28 WEEKS OF PREGNANCY FOR THE PREVENTION
OF PERINATAL HIV IN THAILAND
M. Lallemant, S. Kanshana,  Chalermpantmetagul,et al
 (2nd IAS)
Abstract
Prevention/Treatment Guidelines
 

United States

     Internet Documents

  FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  FULL TEXT PDF DOCUMENT
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines

        Journal Papers, Abstracts, and Commentaries

  Pharmacokinetics and tolerance of zidovudine in preterm infants.
Capparelli EV, Mirochnick M, Dankner WM, et al
J Pediatr 2003 Jan;142(1):47-52
 Abstract

Pharmacokinetics of zidovudine in infants: a population analysis across studies.
Mirochnick M, Capparelli E, Connor
J Clin Pharmacol Ther 1999 Jul;66(1):16-24  
Abstract

  

        Conference Reports, Abstracts, and Posters

  Systemic Pharmacokinetics (PK) of Oral Zidovudine (ZDV) Given During Labor and
Delivery to HIV-1-Infected Pregnant Women
(7 CROI) 
Abstract

 Pharmacokinetics and Intracellular Pharmacology of Zidovudine in HIV-Infected
Women and Newborn Infants.
(6 CROI)   
Abstract		  
Safety
 

        Journal Papers, Abstracts, and Commentaries

 
FULL TEXT ARTICLE
 Haematological Safety of Perinatal Zidovudine in Pregnant HIV-1-Infected Women in Thailand:
Secondary Analysis of a Randomized Trial.
 Briand N, Lallemant M, Jourdain G, et al
PLoS Clin Trials. 2007 Apr 27
 Paper

FULL-TEXT ARTICLE
 Safety of late in utero exposure to zidovudine in infants born to human Collaborativ
Perinatal HIV Transmission Study Group.
Chotpitayasunondh T, Vanprapar N, Simonds RJ, et al.
Pediatrics 2001 Jan;107(1):E5 
Paper
   
  Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS
Clinical Trial Group 076 study.
Sperling RS, Shapiro DE, McSherry GD, et al.
AIDS 1998; 12:1805- 1813
Abstract

        Conference Reports, Abstracts, and Posters

 
POSTER
 Genotypic Resistance Analysis in Women Who Received Intrapartum Nevirapine
Associated to a Short Course of Zidovudine to Prevent Perinatal HIV-1 Transmission:
The Ditrame Plus ANRS 1201/02 Study, Abidjan, Côte d'Ivoire
ML Chaix, C Montcho, DK Ekouevi, et al.   
 (11 CROI)
 PDF Poster       Abstract
 
Resistance
 

        Journal Papers, Abstracts, and Commentaries

 
HIV Type 1 Zidovudine (ZDV) Resistance in Blood and Uterine Cervical Secretions of Pregnant
Women.
 Frenkel LM, McKernan J, Dinh PV, et al
AIDS Res Hum Retroviruses. 2006 Sep;22(9):870-3
 Abstract
 
Lack of resistant mutation development after receiving short-course zidovudine plus
lamivudine to prevent mother-to-child transmission.
 Chokephaibulkit K, Chaisilwattana P, Vanprapar N, et al 
AIDS. 2005 Jul 22;19(11):1231-3.
Abstract
 
Zidovudine Resistance Phenotype and Risk of Perinatal HIV-1 Transmission in Zidovudine
Monotherapy-Treated Mothers With Moderately Advanced Disease.
 Bauer GR, Welles SL, Colgrove RR, et al 
J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):312-9.
 Abstract

Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal
cohort
Masquelier B, Chaix ML, Burgard M, et al. Pediatric HIV Infection Study Group.
J Acquir Immune  Defic Syndr 2001 Jun 1;27(2):99-104
Abstract

HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission
in the women and infants transmission study. The Women and Infants Transmission Study
Group.
 Welles SL, Pitt J, Colgrove R, et al;
AIDS 2000 Feb 18;14(3):263-71  
Abstract 
 
Maternal viral genotypic zidovudine resistance and Infrequent failure of zidovudine therapy
 to prevent perinatal transmission of human immunodeficiency virus type I in pediatric AIDS
Clinical Trials Group protocol 076.
Eastman PS, Shapiro DE, Coombs RW, et al.  
J Infect Dis 1998;177:557-564.
Abstract

        Conference Reports, Abstracts and Posters

 
Antiretroviral resistance mutations among HIV positive pregnant women
C N Edeh, G Babaoye
 (15IAC)
 Abstract
 
DETECTION OF RESISTANCE MUTATIONS IN MOTHERS INFECTED WITH HIV-1 AND
TREATED WITH ZIDOVUDINE (AZT) AS PROPHYLAXIS BEFORE DELIVERY
A. Lindström, A.B. Bohlin, K. Gyllensten, J. Albert
(2ND IAS)
 Abstract
 
Case-control study of perinatal HIV-1 transmission and genotypic and phenotypic markers of
reduced susceptibility to zidovudine (ZDV)
L M Mofenson, J Lambert, E R Stiehm, et al
 (14IAC)
 Abstract
 
Phenotypic Zidovudine (ZDV) Resistance and Perinatal HIV-1 Transmission.
 (8 CROI) 
Abstract
 
Association of Maternal ZDV Use during Pregnancy and Infant ZDV Genotypic Resistance
with Rapid Disease Progression among Infants in the WITS
[7 CROI)
Abstract
 
Adverse Events
 

        Journal Papers, Abstracts, and Commentaries

 
A WEEK-IN-REVIEW FEATURED REPORT
 Placental transfer of Zidovudine in first trimester of pregnancy.
 Siu SS, Yeung JH, Pang MW, et al
Obstet Gynecol. 2005 Oct;106(4):824-7.
 Abstract
 
3'-Azido-3'-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in
human placenta.
Collier AC, Helliwell RJ, Keelan JA
Toxicol Appl Pharmacol. 2003 Oct 15;192(2):164-73
 Abstract

Absence of cardiac toxicity of zidovudine in infants. Pediatric  Pulmonary and Cardiac
Complications of Vertically Transmitted HIV Infection Study Group.
 Lipshultz SE, Easley KA, Orav EJ, et al.  
N Engl J Med 2000 Sep 14;343(11):759-66
Abstract
   
  Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in
infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical
Trials Group 185 Team.
 Lambert JS, Watts DH, Mofenson L, Stiehm ER, et al. 
AIDS 2000 Jul 7;14(10):1389-99
Abstract
   
  FULL-TEXT ARTICLE
 Lack of Long-term Effects of In Utero Exposure to Zidovudine Among Uninfected Children
Born to HIV-Infected Women.
Culnane M, Fowler M, Lee SS, et al.
JAMA 1999 Jan 13;281(2):151-7
Paper 
   
  The Ariel Project: A Prospective Cohort Study of Maternal-Child Transmission of Human
Immunodeficiency Virus Type 1 in the Era of Maternal Antiretroviral Therapy
Van Dyke RB, Korber BT, Popek E, et al. 
J Infect Dis 1999 Feb;179(2):319-28
Abstract

        Conference Reports, Abstracts and Posters

 
Prevalence of Anemia among Women in a Trial of HAART including Zidovudine for PMTCT in
Kisumu, Kenya
 T Thomas, R Masaba, R Ndivo, et al
(14 CROI)
 Abstract
 
Clinically-significant anemia in HIV-infected pregnant women in India is not a major barrier
to use of zidovudine for prevention of maternal to child transmission
Sinha G., Choi J., Nayak U., et al
(XVI International AIDS Conference)
 Abstract

Adverse events in infants receiving 6 months of zidovudine in a pilot study to prevent mother to
child transmission of HIV through breastfeeding, Botswana
S Lockman, I Thior, R Shapiro, 
 (14IAC)
 Abstract
Patient Perceptions/Knowledge/Attitudes
 

       Journal Papers, Abstracts, and Commentaries

 
Concerns and experiences of women participating in a short-term AZT intervention
feasibility study for prevention of HIV transmission from mother-to-child.
 Mawar N, Joshi PL, Sahay S, Bagul RD, Paranjape RS.
Cult Health Sex. 2007 Mar-Apr;9(2):199-207.
 Abstract

Factors associated with HIV-infected women's use or intention to use AZT during
pregnancy.
Siegel K, Lekas HM, Schrimshaw EW, Johnson JK.
 AIDS Educ Prev 2001 Jun;13(3):189-206 
 Abstract

  
Adherence
 

       Journal Papers, Abstracts, and Commentaries
 

  Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results
of a MEMS substudy from the Perinatal Guidelines Evaluation Project.
Ickovics JR, Wilson TE, Royce RA, et al.
J Acquir Immune Defic Syndr 2002 Jul 1;30(3):311-5
 Abstract		  

ZDV Main Page Main New/Newsworthy Home Page

Zidovudine Perinatal Data